- Lineage Cell Therapeutics (LCTX, Financial) to participate in Eyecelerator 2025 panel on novel drug delivery for glaucoma and retina.
- The event is sponsored by the American Academy of Ophthalmology (AAO) and features key biotech companies.
- The panel will take place on May 2, 2025, at Grand Hyatt, Deer Valley, Utah.
Lineage Cell Therapeutics (LCTX), a clinical-stage biotechnology company, has announced its participation in the Eyecelerator@Park City 2025 conference. The company’s CEO, Brian M. Culley, will join a panel of distinguished experts to discuss groundbreaking approaches to drug delivery for the treatment of glaucoma and retina conditions. This session, titled "I Shall Be Released: Novel Drug Delivery Approaches for Glaucoma and Retina," will include representatives from REGENXBIO Inc., Regenerative Patch Technologies, and Neurotech Pharmaceuticals, among others.
The panel discussion will be chaired by Dr. Allen C. Ho, the Eyecelerator Retina Program Director and an attending surgeon at Wills Eye Hospital. Scheduled for May 2, 2025, from 12:30 pm to 1:30 pm MDT, the event will be held at the Grand Hyatt in Deer Valley, Utah. The American Academy of Ophthalmology (AAO) sponsors the conference, with a focus on innovation in eye care.
For those unable to attend, the panel presentation will be accessible on Lineage's website following the conference. This initiative underscores Lineage’s commitment to advancing therapies in unmet medical needs, leveraging its proprietary technology platform to develop “off-the-shelf” cell therapies.
Lineage Cell Therapeutics (LCTX, Financial) continues to make strides in biotechnology, and their involvement in such forums highlights their active role in the scientific and medical communities.
